Who founded Telo Therapeutics, Inc.?

Telo Therapeutics, Inc. was founded by Rob Bell, Robert Bell Ph.D. in 2015.

Who are Telo Therapeutics, Inc.'s investors?

Telo Therapeutics, Inc.'s investors include Mission Biocapital.

How much funding has Telo Therapeutics, Inc. raised?

Telo Therapeutics, Inc. has disclosed $4.7M raised across 1 round.

Where is Telo Therapeutics, Inc. headquartered?

Telo Therapeutics, Inc. is headquartered in San Francisco, US.

Telo Therapeutics, Inc.

San Francisco, US · Founded 2015 · Delaware corporation · 2 employees on LinkedIn · 1 known investors

Find your way into Telo Therapeutics, Inc.

601 people in our graph share verified history with the Telo Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.

Paul Kwanunlockedknows Robert Bell · together at Stanford University (overlapped)

×2knows the team · via Boston College

×3knows the team · via UCSF

×6knows the team · via Stanford University

Telo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments. Its lead program targets multiple myeloma and other cancers, and the company is raising a Series A to advance toward IND and a Phase 1 trial.

Biotech Healthtech Medical Devices

Founders & leadership

Telo Therapeutics, Inc. was founded in 2015 by Rob Bell and Robert Bell Ph.D..

Rob Bell inCo-Founder and CEORob Bell holds a Bachelor's degree from Boston College and a PhD in cancer genetics and molecular biology from UCSF, where he conducted graduate research under Dr. Joseph Costello. He is the founder and CEO of Telo Therapeutics, a San Francisco-based biotechnology company developing small-molecule inhibitors of nuclear transport for cancer treatment.

Robert Bell Ph.D.CEO & Co-Founder

Robert Bell inCo-Founder and CEO

Joseph CostelloNamed on SEC filing

Michael D. Taylor inNamed on SEC filingOperating Partner at Mission Biocapital

Board

Robert G. Blazej inBoard MemberPartner at Mission Biocapital

Investors · 1

Mission BiocapitalreportedSan Francisco · $500Kvia Robert Blazej · board

Reported raises · per SEC filings

Form D private placements

$4.7M disclosed across 1 round · 2021

▶$4.7MraisedJun 2022 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Robert G. BlazejDirector
Robert BellExecutive Officer, Director
Joseph CostelloDirector
Michael D. TaylorDirector

Offering amount: $10.2M
Amount sold: $4.7M
First sale: Jun 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Dialectic Therapeutics22 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.

Solu20 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Applied Therapeutics16 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.

Relay15 shared keywordsRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.

Companies competing with Telo Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

San Francisco California based Telo Therapeutics has raised a $4.71 Million Seed Round. - intelligence360intelligence360.news · Jul 2022

MIF investment - Telo Therapeutics, Inc.telotherapeutics.com · Jun 2019

Frequently asked questions

What does Telo Therapeutics, Inc. do?: Telo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments. Its lead program targets multiple myeloma and other cancers, and the company is raising a Series A to advance toward IND and a Phase 1 trial.
Who founded Telo Therapeutics, Inc.?: Telo Therapeutics, Inc. was founded by Rob Bell, Robert Bell Ph.D. in 2015.
Who are Telo Therapeutics, Inc.'s investors?: Telo Therapeutics, Inc.'s investors include Mission Biocapital.
How much funding has Telo Therapeutics, Inc. raised?: Telo Therapeutics, Inc. has disclosed $4.7M raised across 1 round.
Where is Telo Therapeutics, Inc. headquartered?: Telo Therapeutics, Inc. is headquartered in San Francisco, US.